Retinal Vein Occlusion Market (Type: Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion; and Treatment Type: Anti-VEGF Drugs, Corticosteroid Drugs, Pan-retinal Photocoagulation Therapy, and Laser Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2030

Description

Telehealth Services Help Revive Market Growth During COVID-19 Pandemic

Stakeholders in the retinal vein occlusion market are under scrutiny to provide efficient care and support to patients during the ongoing COVID-19 pandemic. Pharmaceutical companies are boosting their production capabilities to ensure the robust supply of drugs and therapeutics in hospitals, clinics, and emergency settings. As such, the pandemic has compelled patients to delay or cancel their treatment, which is affecting the sales of therapeutics. Nevertheless, telehealth services and mobile apps are helping to revive the growth of the retinal vein occlusion market.

An increasing number of individuals are opting for remote health services. This has led to the demand for telehealth services and mobile apps during the ongoing pandemic. Mass vaccination programs are anticipated to boost the revenue flow in the global economy.

Full Ophthalmologic Examination, VA Measurement Necessary to Improve Patient Outcomes

The retinal vein occlusion market is expected to surpass US$ 32.5 Bn by 2031. However, there is a need for full ophthalmologic examination when retinal vein occlusion (RVO) is suspected, along with a VA (Visual Acuity) measurement in order to improve patient outcomes. There is increased awareness about iris examination to rule out neovascularization.

In order to improve clinical numbers, healthcare providers are taking into consideration the medical history and paying attention to examinations carried out for achieving efficient diagnosis of RVO. The presence of macular edema (ME) and the extent of retinal ischemia are being evaluated. Healthcare companies are gaining awareness that long-term monitoring of patients should be individualized to combine maintenance with practicability. While steroids may be considered in patients with systemic cardiovascular risk, surgery is advisable only for few and specific patient cases.

Ranibizumab Gains Prominence in U.S., Indian Healthcare Systems for RVO Treatment

Retinal vein occlusion is the second-most common retinal vascular disease, which can potentially lead to loss of vision. Since ranibizumab is approved by the U.S. Food and Drug Administration (USFDA) for the treatment of ME secondary to RVO. This is benefitting stakeholders in the India retinal vein occlusion market since the Drug Controller General of India (DCGI) has also approved ranibizumab for the treatment of macular edema caused by retinal vein occlusion.

Large, randomized, and controlled clinical trials are substantiating the efficacy of anti-VEGF (vascular endothelial cell growth factor) agents, including ranibizumab for the treatment of ME secondary to RVO. Such findings are translating into revenue opportunities for companies in the retinal vein occlusion market. Ranibizumab for the treatment of ME caused by branch retinal vein occlusion (BRVO) showed rapid and sustained visual improvement in patients who received monthly intravitreal injections of the drug.

Intravitreal Injections of VEGF Inhibitors Result in Better Visual, Anatomic Outcomes

The high prevalence of cardiovascular and other systemic diseases in Nepal is contributing to the growth of the Nepal retinal vein occlusion market. Treatment options such as laser photocoagulation and intravitreal injections of either VEGF inhibitors or steroids are being publicized. It has been found that intravitreal injections of VEGF inhibitors for RVO result in good visual and anatomic outcomes as compared to macular laser photocoagulation or intravitreal injections of triamcinolone.

Companies in the retinal vein occlusion market are increasing their production capabilities in VEGF inhibitors that are gaining popularity as the preferred first line agents in the treatment of RVO. It has been found that the choice of VEGF inhibitors among countries varies as per their drug regulatory processes.

Laser Coagulation May Effectively Improve Visual Prognosis in BRVO Patients

The retinal vein occlusion market is slated to clock a favorable CAGR of 7.3% during the forecast period. In order to properly diagnose BRVO, there is a need for specialized tests such as fluorescein angiography, ocular coherence tomography (OCT), and color fundus photography. Apart from preventive care, clinicians are relying on laser therapy to help manage the symptoms of branch retinal vein occlusion.

It has been found that laser coagulation could effectively improve visual prognosis in patients with BRVO during three years of follow-up. Such trends are contributing to the growth of the global retinal vein occlusion market. It has been found that multiple laser treatments are required to achieve the desired results in patients. VitreoRetinal Surgery, PLLC - a provider of advanced retinal care in Minessota, is gaining recognition for offering laser treatment to BRVO patients.

Different Treatment Modalities Improve Clinical Numbers

Companies in the retinal vein occlusion market are increasing their output capacities in corticosteroid drugs that help to combat the inflammatory components, which lead to edema. On the other hand, healthcare professionals are acquiring proficiency in the focal laser therapy. This treatment provides lasers to areas of swelling to cause a reduction in edema.

Stakeholders in the retinal vein occlusion market are increasing their research in the pan-retinal photocoagulation therapy. This treatment is used when patients have new blood vessel formation following the retinal vein occlusion. On the other hand, anti-vascular endothelial growth factor (anti-VEGF) medications such as Lucentis, Avastin, and Eylea are being used in cases of BRVO where neovascularization or macular edema is present. These medications are directly injected in the eye and help inhibit abnormal blood vessels from growing.

Laser Photocoagulation Treatment Reduce Severity of Retinal Neovascularization

One of the serious problems in BRVO is that of retinal neovascularization. In advanced cases, abnormal blood vessels grow from the retina into the vitreous gel of the eye. Since these vessels are very fragile, this can lead to major bleeding, also known as vitreous hemorrhage, and scar tissue formation. Hence, healthcare providers in the retinal vein occlusion market are increasing the availability of the laser photocoagulation treatment to the peripheral retina, which is found to be very helpful in this situation.

Laser treatment usually results in stabilization or even regression of the blood vessel growth. The bleeding caused due to retinal neovascularization may sometimes clear on its own but in a few cases will require the need for operation to remove the blood and the vitreous gel.

Analysts’ Viewpoint

Telehealth services and mobile apps are encouraging individuals to seek professional treatment in cases where the severity of RVO is high amid the ongoing COVID-19 outbreak. OCT, ophthalmoscopy, and fluorescein angiography are helping in effective diagnosis of RVO. However, there is still a need for taking into consideration the medical history of patients while evaluating the treatment options for central retinal vein occlusion. Hence, stakeholders in the retinal vein occlusion market should work closely with medical practitioners to gain awareness about any risk factors that raise suspicion for a vein occlusion. Such efforts will help improve therapeutics and better patient outcomes.

Retinal Vein Occlusion Market: Overview

This report analyzes the current scenario and future prospects of the global retinal vein occlusion market. Retinal vein occlusion is the blockage of the retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally. A blood clot causes a blockage in the vein, which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. Rise in prevalence of eye diseases globally, increase in geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments are the major drivers of the global retinal vein occlusion market.

The report includes an elaborate executive summary, which provides a snapshot of various segments of the global retinal vein occlusion market. It also provides information and data analysis of the global retinal vein occlusion market about segments based on type, treatment type, and region.

The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global retinal vein occlusion market

The report includes company profiles, which provide information about their business, product portfolios, strategic overview, and competition landscape in the global retinal vein occlusion market

The report on the global retinal vein occlusion market offers market attractiveness analysis of regions and segments

The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global retinal vein occlusion market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global retinal vein occlusion market.

Retinal Vein Occlusion Market: Key Segments

In terms of type, the global retinal vein occlusion market has been bifurcated into central retinal vein occlusion and branch retinal vein occlusion. The central retinal vein occlusion segment dominated the global retinal vein occlusion market in 2020, and the trend is projected to continue during the forecast period.

Based on treatment type, the global retinal vein occlusion market has been classified into anti-VEGF drugs, corticosteroid drugs, pan-retinal photocoagulation therapy, and laser therapy. The anti-VEGF drugs segment held major share of the global retinal vein occlusion market in 2020. Rise in prevalence and incidence of diabetes drives the segment.

Market size and forecast for each of these segments and sub-segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided from 2021 to 2031, considering 2020 as the base year, and 2017, 2018, and 2019 as historical years.

Retinal Vein Occlusion Market: Regional Outlook

The global retinal vein occlusion market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The retinal vein occlusion market study also covers the competitive scenario in these regions.

Retinal Vein Occlusion Market Players

Key players in the global retinal vein occlusion market have been profiled based on attributes such as company overview, product portfolio, financial overview, strategic overview, recent developments, and competitive business strategies

Key Questions Answered in Retinal Vein Occlusion Market Report

  • What are the major drivers, restraints, and opportunities in the market?
  • What are the revenue share projections of key segments of the global retinal vein occlusion market during the forecast period?
  • Which segment is likely to lead the global retinal vein occlusion market in terms of revenue by 2031?
  • How technological developments are widening the scope for the global retinal vein occlusion market?
  • What is the market position of different companies operating in the global retinal vein occlusion market?

Retinal Vein Occlusion Market – Segmentation

Type

  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion

Treatment Type

  • Anti-VEGF Drugs
  • Corticosteroid Drugs
  • Pan-retinal Photocoagulation Therapy
  • Laser Therapy

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Retinal Vein Occlusion Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Retinal Vein Occlusion Market Analysis and Forecast, 2017–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Industry Events

    5.2. COVID-19 Pandemic Impact on Industry (value chain and short-/ mid-/ long-term impact)

6. Global Retinal Vein Occlusion Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast by Type, 2017–2030

        6.3.1. Central Retinal Vein Occlusion

        6.3.2. Branch Retinal Vein Occlusion

    6.4. Market Attractiveness Analysis, by Type

7. Global Retinal Vein Occlusion Market Analysis and Forecast, by Treatment Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Treatment Type, 2017–2030

        7.3.1. Anti-VEGF Drugs

        7.3.2. Corticosteroid Drugs

        7.3.3. Pan-retinal Photocoagulation Therapy

        7.3.4. Laser Therapy

    7.4. Market Attractiveness Analysis, by Treatment Type

8. Global Retinal Vein Occlusion Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Country/Sub-region/Region

9. North America Retinal Vein Occlusion Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Type, 2017–2030

        9.2.1. Central Retinal Vein Occlusion

        9.2.2. Branch Retinal Vein Occlusion

    9.3. Market Value Forecast, by Treatment Type, 2017–2030

        9.3.1. Anti-VEGF Drugs

        9.3.2. Corticosteroid Drugs

        9.3.3. Pan-retinal Photocoagulation Therapy

        9.3.4. Laser Therapy

    9.4. Market Value Forecast, by Country, 2017–2030

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Type

        9.5.2. By Treatment Type

        9.5.3. By Country

10. Europe Retinal Vein Occlusion Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017–2030

        10.2.1. Central Retinal Vein Occlusion

        10.2.2. Branch Retinal Vein Occlusion

    10.3. Market Value Forecast, by Treatment Type, 2017–2030

        10.3.1. Anti-VEGF Drugs

        10.3.2. Corticosteroid Drugs

        10.3.3. Pan-retinal Photocoagulation Therapy

        10.3.4. Laser Therapy

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2030

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Type

        10.5.2. By Treatment Type

        10.5.3. By Country/Sub-region

11. Asia Retinal Vein Occlusion Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017–2030

        11.2.1. Central Retinal Vein Occlusion

        11.2.2. Branch Retinal Vein Occlusion

    11.3. Market Value Forecast, by Treatment Type, 2017–2030

        11.3.1. Anti-VEGF Drugs

        11.3.2. Corticosteroid Drugs

        11.3.3. Pan-retinal Photocoagulation Therapy

        11.3.4. Laser Therapy

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2030

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia

    11.5. Market Attractiveness Analysis

        11.5.1. By Type

        11.5.2. By Treatment Type

        11.5.3. By Country/Sub-region

12. Latin America Retinal Vein Occlusion Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017–2030

        12.2.1. Central Retinal Vein Occlusion

        12.2.2. Branch Retinal Vein Occlusion

    12.3. Market Value Forecast, by Treatment Type, 2017–2030

        12.3.1. Anti-VEGF Drugs

        12.3.2. Corticosteroid Drugs

        12.3.3. Pan-retinal Photocoagulation Therapy

        12.3.4. Laser Therapy

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2030

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Type

        12.5.2. By Treatment Type

        12.5.3. By Country/Sub-region

13. Middle East & Africa Retinal Vein Occlusion Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017–2030

        13.2.1. Central Retinal Vein Occlusion

        13.2.2. Branch Retinal Vein Occlusion

    13.3. Market Value Forecast, by Treatment Type, 2017–2030

        13.3.1. Anti-VEGF Drugs

        13.3.2. Corticosteroid Drugs

        13.3.3. Pan-retinal Photocoagulation Therapy

        13.3.4. Laser Therapy

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2030

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Type

        13.5.2. By Treatment Type

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2020

    14.3. Company Profiles

        14.3.1. Alimera Sciences

            14.3.1.1. Company Description

            14.3.1.2. Business Overview

            14.3.1.3. Financial Overview

            14.3.1.4. Strategic Overview

            14.3.1.5. SWOT Analysis

        14.3.2. Allergan (AbbVie, Inc.)

            14.3.2.1. Company Description

            14.3.2.2. Business Overview

            14.3.2.3. Financial Overview

            14.3.2.4. Strategic Overview

            14.3.2.5. SWOT Analysis

        14.3.3. Annexin Pharmaceuticals AB (publ)

            14.3.3.1. Company Description

            14.3.3.2. Business Overview

            14.3.3.3. Strategic Overview

            14.3.3.4. SWOT Analysis

        14.3.4. Bayer AG

            14.3.4.1. Company Description

            14.3.4.2. Business Overview

            14.3.4.3. Financial Overview

            14.3.4.4. Strategic Overview

            14.3.4.5. SWOT Analysis

        14.3.5. Carl Zeiss AG

            14.3.5.1. Company Description

            14.3.5.2. Business Overview

            14.3.5.3. Financial Overview

            14.3.5.4. SWOT Analysis

        14.3.6. F. Hoffmann-La Roche Ltd.

            14.3.6.1. Company Description

            14.3.6.2. Business Overview

            14.3.6.3. Financial Overview

            14.3.6.4. Strategic Overview

            14.3.6.5. SWOT Analysis

        14.3.7. Iridex Corporation

            14.3.7.1. Company Description

            14.3.7.2. Business Overview

            14.3.7.3. Financial Overview

            14.3.7.4. Strategic Overview

            14.3.7.5. SWOT Analysis

        14.3.8. Lumenis

            14.3.8.1. Company Description

            14.3.8.2. Business Overview

            14.3.8.3. Strategic Overview

            14.3.8.4. SWOT Analysis

        14.3.9. Nidek Co., Ltd.

            14.3.9.1. Company Description

            14.3.9.2. Business Overview

            14.3.9.3. Strategic Overview

            14.3.9.4. SWOT Analysis

        14.3.10. Novartis AG

            14.3.10.1. Company Description

            14.3.10.2. Business Overview

            14.3.10.3. Financial Overview

            14.3.10.4. Strategic Overview

            14.3.10.5. SWOT Analysis

        14.3.11. Regeneron Pharmaceuticals, Inc.

            14.3.11.1. Company Description

            14.3.11.2. Business Overview

            14.3.11.3. Financial Overview

            14.3.11.4. Strategic Overview

            14.3.11.5. SWOT Analysis

        14.3.12. Topcon Corporation

            14.3.12.1. Company Description

            14.3.12.2. Business Overview

            14.3.12.3. Financial Overview

            14.3.12.4. Strategic Overview

            14.3.12.5. SWOT Analysis

Choose License Type

Checkout Inquiry Sample